ImmuneBridge is developing the next generation of allogeneic cellular medicines to make curative cancer therapies accessible to everyone, and we’re starting with NK cell-based immunotherapies.

Latest News Entry
ImmuneBridge Raises $12M from M Ventures and Insight Partners to Advance Novel Natural Killer (NK) Cell-based Immunotherapies

Biotech company taps into human diversity for next-generation NK cell therapies.

all portfolio news